Back to News
Feb 2, 2026 4:24 AM

Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends

Kyowa Kirin Co., Ltd. and Amgen Inc. (NASDAQ:AMGN) terminated on Friday the current rocatinlimab development and commercialization collaboration.

• Amgen stock is trading at elevated levels. Where are AMGN shares going?

Kyowa Kirin will regain control of the global rocatinlimab program, including regulatory filings and future commercialization.

The business decision is the result of a strategic portfolio prioritization by Amgen.

In June 2021, Amgen and Kyowa Kirin agreed to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for atopic dermatitis, with potential in other autoimmune diseases.

Amgen paid $400 million upfront payment, and Kyowa Kirin was eligible to receive milestone payments worth up to an additional $850 million.

In September 2025, the companies released preliminary topline results from the ASCEND study evaluating rocatinlimab in adults and adolescents with moderate to severe atopic dermatitis (AD).

The analysis focused on adults who completed the first 24 weeks of therapy in a previous ROCKET trial and ...